{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T20:35:06Z","timestamp":1795034106215,"version":"4.10.2"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,12]]},"abstract":"<jats:p>Ipilimumab can induce long-term survival in 20% of patients with metastatic melanoma. Concurrent chronic medications may impact the patient\u2019s immune system, possess antimelanoma properties, and potentially affect clinical outcomes. This retrospective study sought to describe the efficacy and toxicity effects of 12 classes of chronic medications in metastatic melanoma patients treated with ipilimumab. A total of 159 adults who received ipilimumab for metastatic melanoma at Mayo Clinic (Rochester, Minnesota, USA) from 1 March 2011 through 31 December 2014 were included. Classes of chronic medications included statins, metformin, \u03b2-blockers, angiotensin-converting enzyme inhibitors\/angiotensin-receptor blockers, calcium channel blockers, aspirin, non-steroidal anti-inflammatory drugs, H1 and H2 receptor antagonists, proton pump inhibitors (PPIs), antidepressants, and vitamin D supplements. Of the 12 medication classes, only PPIs were found to have an increased odds of experiencing a partial response or a complete response to ipilimumab [odds ratio: 3.73; confidence interval (CI): 1.26\u201311.04; <jats:italic toggle=\"yes\">P<\/jats:italic>=0.02] on the basis of a case\u2013control analysis. Although not significant, PPI use also trended toward improved overall survival and progression-free survival (hazard ratio: 0.44; CI: 0.17\u20131.15; <jats:italic toggle=\"yes\">P<\/jats:italic>=0.09; and hazard ratio: 0.6; CI: 0.34\u20131.06; <jats:italic toggle=\"yes\">P<\/jats:italic>=0.08, respectively) on the basis of Kaplan\u2013Meier and Cox proportional hazard modeling. No medication class was associated with an increased risk of grades 3\u20135 immune-related adverse events with ipilimumab on the basis of case\u2013control analysis. In summary, patients on PPIs may be more likely to experience a partial response\/complete response following ipilimumab therapy. Because of the small sample size and the retrospective nature of this work, these findings are only descriptive and further study should be carried out. Other classes of chronic medications did not produce statistically significant effects for any of the measured outcomes.<\/jats:p>","DOI":"10.1097\/cmr.0000000000000299","type":"journal-article","created":{"date-parts":[[2016,9,3]],"date-time":"2016-09-03T12:59:57Z","timestamp":1472907597000},"page":"609-615","source":"Crossref","is-referenced-by-count":56,"title":["Effects of commonly used chronic medications on the outcomes of ipilimumab therapy in patients with metastatic melanoma"],"prefix":"10.1097","volume":"26","author":[{"given":"Jarrett J.","family":"Failing","sequence":"first","affiliation":[{"name":"Internal Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi D.","family":"Finnes","sequence":"additional","affiliation":[{"name":"Pharmacy Services"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa A.","family":"Kottschade","sequence":"additional","affiliation":[{"name":"Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob B.","family":"Allred","sequence":"additional","affiliation":[{"name":"Cancer Center Statistics, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetomir N.","family":"Markovic","sequence":"additional","affiliation":[{"name":"Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230902","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.mayocp.2014.02.002","article-title":"Latest advances in chemotherapeutic, targeted, and immune approaches in the treatment of metastatic melanoma","volume":"89","author":"Shah","year":"2014","journal-title":"Mayo Clin Proc"},{"key":"R2-20230902","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"R3-20230902","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N Engl J Med"},{"key":"R4-20230902","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1093\/annonc\/mdu441","article-title":"Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies","volume":"25","author":"Lebb\u00e9","year":"2014","journal-title":"Ann Oncol"},{"key":"R5-20230902","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s12916-015-0455-8","article-title":"Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis","volume":"13","author":"Bertrand","year":"2015","journal-title":"BMC Med"},{"key":"R6-20230902","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1158\/1078-0432.CCR-08-1980","article-title":"Evidence of systemic Th2-driven chronic inflammation in patients with metastatic melanoma","volume":"15","author":"Nevala","year":"2009","journal-title":"Clin Cancer Res"},{"key":"R7-20230902","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1158\/1940-6207.CAPR-14-0018","article-title":"Aspirin and other NSAIDs as chemoprevention agents in melanoma","volume":"7","author":"Goodman","year":"2014","journal-title":"Cancer Prev Res (Phila)"},{"key":"R8-20230902","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.ejphar.2011.07.004","article-title":"In vitro and in vivo anti-melanoma action of metformin","volume":"668","author":"Janjetovic","year":"2011","journal-title":"Eur J Pharmacol"},{"key":"R9-20230902","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1016\/j.ejca.2007.09.004","article-title":"Is statin use associated with a reduced incidence, a reduced Breslow thickness or delayed metastasis of melanoma of the skin?","volume":"43","author":"Koomen","year":"2007","journal-title":"Eur J Cancer"},{"key":"R10-20230902","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/j.mayocp.2013.09.001","article-title":"Effect of \u03b2-blockers and other antihypertensive drugs on the risk of melanoma recurrence and death","volume":"88","author":"De Giorgi","year":"2013","journal-title":"Mayo Clin Proc"},{"key":"R11-20230902","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/ijc.25009","article-title":"pH-dependent antitumor activity of proton pump inhibitors against human melanoma is mediated by inhibition of tumor acidity","volume":"127","author":"De Milito","year":"2010","journal-title":"Int J Cancer"},{"issue":"Pt B","key":"R12-20230902","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.canlet.2014.10.017","article-title":"Lansoprazole induces sensitivity to suboptimal doses of paclitaxel in human melanoma","volume":"356","author":"Azzarito","year":"2015","journal-title":"Cancer Lett"},{"key":"R13-20230902","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1159\/000007686","article-title":"Does cimetidine improve prospects for cancer patients?. A reappraisal of the evidence to date","volume":"60","author":"Siegers","year":"1999","journal-title":"Digestion"},{"key":"R14-20230902","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/00008390-199604000-00003","article-title":"In vitro effect of histamine and histamine H1 and H2 receptor antagonists on cellular proliferation of human malignant melanoma cell lines","volume":"6","author":"Reynolds","year":"1996","journal-title":"Melanoma Res"},{"key":"R15-20230902","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/jid.2014.373","article-title":"Inhibition of human melanoma growth by a non-cardioselective \u03b2-blocker","volume":"135","author":"Wrobel","year":"2015","journal-title":"J Invest Dermatol"},{"key":"R16-20230902","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S1734-1140(13)71045-4","article-title":"Inhibitory effect of antidepressants on B16F10 melanoma tumor growth","volume":"65","author":"Grygier","year":"2013","journal-title":"Pharmacol Rep"},{"key":"R17-20230902","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/00008390-200504000-00001","article-title":"Lovastatin-induced apoptosis in human melanoma cell lines","volume":"15","author":"Shellman","year":"2005","journal-title":"Melanoma Res"},{"key":"R18-20230902","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/CMR.0b013e3282f60097","article-title":"Simvastatin inhibits growth via apoptosis and the induction of cell cycle arrest in human melanoma cells","volume":"18","author":"Saito","year":"2008","journal-title":"Melanoma Res"},{"key":"R19-20230902","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S0959-8049(97)10034-X","article-title":"Potentiated antitumour effects of cisplatin and lovastatin against MmB16 melanoma in mice","volume":"34","author":"Feleszko","year":"1998","journal-title":"Eur J Cancer"},{"key":"R20-20230902","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/ijc.10440","article-title":"Lovastatin potentiates antitumor activity of doxorubicin in murine melanoma via an apoptosis-dependent mechanism","volume":"100","author":"Feleszko","year":"2002","journal-title":"Int J Cancer"},{"key":"R21-20230902","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1002\/cam4.285","article-title":"Statin use and its effect on all-cause mortality of melanoma patients: a population-based Dutch cohort study","volume":"3","author":"Livingstone","year":"2014","journal-title":"Cancer Med"},{"key":"R22-20230902","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/bjc.2013.762","article-title":"Statin use is not associated with reduced risk of skin cancer: a meta-analysis","volume":"110","author":"Li","year":"2014","journal-title":"Br J Cancer"},{"key":"R23-20230902","doi-asserted-by":"crossref","first-page":"e199","DOI":"10.1038\/cddis.2011.86","article-title":"Metformin inhibits melanoma development through autophagy and apoptosis mechanisms","volume":"2","author":"Tomic","year":"2011","journal-title":"Cell Death Dis"},{"key":"R24-20230902","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/1479-5876-9-76","article-title":"Combination therapy with vemurafenib (PLX4032\/RG7204) and metformin in melanoma cell lines with distinct driver mutations","volume":"9","author":"Niehr","year":"2011","journal-title":"J Transl Med"},{"key":"R25-20230902","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1006\/jsre.1996.0092","article-title":"Vitamin D receptor and growth inhibition by 1,25-dihydroxyvitamin D3 in human malignant melanoma cell lines","volume":"61","author":"Evans","year":"1996","journal-title":"J Surg Res"},{"key":"R26-20230902","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1002\/ijc.29334","article-title":"25-Hydroxyvitamin D2 \/D3 levels and factors associated with systemic inflammation and melanoma survival in the Leeds Melanoma Cohort","volume":"136","author":"Newton-Bishop","year":"2015","journal-title":"Int J Cancer"},{"key":"R27-20230902","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1016\/j.ejca.2014.06.024","article-title":"Vitamin D and melanoma and non-melanoma skin cancer risk and prognosis: a comprehensive review and meta-analysis","volume":"50","author":"Caini","year":"2014","journal-title":"Eur J Cancer"},{"key":"R28-20230902","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1186\/1471-2407-14-780","article-title":"Adjuvant therapy with high dose vitamin D following primary treatment of melanoma at high risk of recurrence: a placebo controlled randomised phase II trial (ANZMTG 02.09 Mel-D)","volume":"14","author":"Saw","year":"2014","journal-title":"BMC Cancer"},{"key":"R29-20230902","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.1016\/j.ejca.2013.07.141","article-title":"\u03b2-Blocker use and all-cause mortality of melanoma patients: results from a population-based Dutch cohort study","volume":"49","author":"Livingstone","year":"2013","journal-title":"Eur J Cancer"},{"key":"R30-20230902","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.mayocp.2014.06.001","article-title":"Effect of \u03b2-adrenergic blockers and other antihypertensive drugs on the risk of melanoma recurrence and death-I","volume":"89","author":"Moser","year":"2014","journal-title":"Mayo Clin Proc"},{"key":"R31-20230902","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.canep.2009.10.005","article-title":"Melanoma incidence and exposure to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers","volume":"33","author":"Koomen","year":"2009","journal-title":"Cancer Epidemiol"}],"container-title":["Melanoma Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00008390-201612000-00009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T03:17:31Z","timestamp":1693624651000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00008390-201612000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/cmr.0000000000000299","relation":{},"ISSN":["0960-8931"],"issn-type":[{"value":"0960-8931","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]}}}